MedTrace Logo

Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas

NCT06089941 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2026-02-20

No results posted yet for this study

Summary

The purpose of this study is to assess the feasibility of analyzing circulating tumor DNA (ctDNA) as a biomarker using the shallow whole genome sequencing (lpWGS) technique coupled with deep sequencing of a targeted panel of genes (NGS), in a population of patients with newly diagnosed or relapsed/refractory peripheral T-cell lymphoma (PTCL).

Conditions

  • Peripheral T Cell Lymphoma

Interventions

OTHER

circulating tumoral DNA detection

blood samples taken at diagnosis, mid-treatment, end of treatment and in the event of relapse

Sponsors & Collaborators

  • IDEOGEN

    collaborator UNKNOWN

  • Centre Henri Becquerel

    lead OTHER

Principal Investigators

  • Vincent Camus · Centre Henri Becquerel

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2025-11-04
Completion
2026-11-04

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06089941 on ClinicalTrials.gov